ODI Pharma AB (publ) reported group earnings results for the second quarter and six months ended December 31, 2020. For the quarter, the company reported net sales amounted to SEK 0. The Group's loss after financial items amounted to SEK 771,779. Loss per share amounted to SEK 0.05. For the six months, the company reported the Group's net sales amounted to SEK 0. The Group's loss after financial items amounted to SEK 2,039,886. Loss per share amounted to SEK 0.13.